Sexton Biotechnologies
Sexton Biotechnologies is a private Indianapolis-based biotechnology company founded in 2019, with 11-50 employees and co-founders Vicky Tran and Monica Wight. In September 2019, it raised $5,000,000 from BioCrossroads, BioLife Solutions, Casdin Capital, and Cook Regentec.
- Company typePublic
- Founded2019
- HeadquartersIndianapolis, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sexton Biotechnologies does
Sexton Biotechnologies is a private biotechnology company founded in 2019 and headquartered in Indianapolis, Indiana. The company operates with 11-50 employees and is led by co-founders Vicky Tran and Monica Wight, both of whom are focused on business development. Sexton's corporate website is sextonbiotechnologies.com. In September 2019, Sexton closed a $5,000,000 funding round from an investor syndicate that included BioCrossroads, BioLife Solutions (NASDAQ: BLFS), Casdin Capital, and Cook Regentec; the lead investor was not disclosed in the available data.
The aggregated source material does not contain direct first-party detail on Sexton's specific product portfolio, underlying technology, customer base, pricing model, or revenue mechanics. Substantial product, technology, certification, customer, and channel data in the input explicitly describes BioLife Solutions Inc. — a publicly traded biopreservation media and cell processing company headquartered in Bothell, Washington, and a disclosed investor in Sexton. That BioLife content has not been attributed to Sexton in this analysis. As a result, Sexton's specific market positioning, product line, and operating model cannot be characterized from the available evidence, and the data gap is the dominant feature of the company profile.
Sexton Biotechnologies firmographics
Firmographics- Name
- Sexton Biotechnologies
- Legal name
- BioLife Solutions Inc.
- Website
- https://sextonbiotechnologies.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sexton Biotechnologies is a private Indianapolis-based biotechnology company founded in 2019, with 11-50 employees and co-founders Vicky Tran and Monica Wight. In September 2019, it raised $5,000,000 from BioCrossroads, BioLife Solutions, Casdin Capital, and Cook Regentec.
- Ownership category
- akta.pro rank
Sexton Biotechnologies industry classification
Industry- Product category
- Biopreservation and Cell Processing Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)
- akta.pro secondary industries
- Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG)
Keywords
Where Sexton Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Indianapolis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sexton Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Biopreservation Media Products: Sale of proprietary freeze media products (CryoStor, HypoThermosol FRS, BloodStor) and cell thawing media to biopharmaceutical, biobanking, and research customers. Products are sold in various sizes (100mL, 500mL) and configurations.
- Cell Performance Solutions: Human platelet lysate products (Stemulate-CP, nLiven PR, T-Liven PR) sold as media supplements for cell expansion in clinical and commercial manufacturing applications.
- Processing and Handling Equipment: Automated aliquoting systems (Signata CT-5), cryogenic storage vials (CellSeal), and fluid management accessories for CGT manufacturing workflows.
- Regulatory Support Services: Master File Letter services for IND and BLA submissions, GMP-ready ancillary materials documentation, Certificates of Analysis, and Safety Data Sheets supporting regulatory submission readiness.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Products available in standard sizes (100 mL and 500 mL) |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Sexton Biotechnologies product offering
Product offeringCore offering
Sexton Biotechnologies is a private biotechnology company based in Indianapolis, founded in 2019. Per the available company and product data, it is associated with a portfolio of biopreservation media, human platelet lysate cell performance products, and automated cell processing and cryogenic storage equipment used in cell and gene therapy manufacturing workflows. Its offerings span freeze and storage media, pathogen-reduced platelet lysates, and closed-system fill/finish and cryogenic handling instruments.
Product overview
BioLife Solutions offers a comprehensive portfolio of biopreservation and cell processing products organized into three main categories: (1) Cell Performance Solutions featuring human platelet lysates (Stemulate-CP, nLiven PR, T-Liven PR) that provide media supplements for reproducible cell performance over FBS and chemically defined media; (2) Processing & Handling Solutions including the Signata CT-5 automated aliquoting system, CellSeal Connect closed-system vials, and CellSeal CryoCase rigid CGT containers; and (3) Biopreservation Solutions comprising CryoStor freeze media, HypoThermosol FRS hypothermic storage media, BloodStor cryopreservation media, and Cell Thawing Media. The company's platform is embedded in over 700+ customer clinical applications, serving the regenerative medicine, biobanking, and drug discovery industries.
Differentiator
Problem solved
Functional benefit
Products and services
- Stemulate-CP Human Platelet Lysate (hPL) A xeno- and heparin-free pooled human platelet lysate used globally in clinical stem cell and immuno-oncology applications. Available in 100 mL and 500 mL sizes, manufactured from outdated FDA/AABB approved apheresis platelet units under ISO 9001:2015 Quality Management System.
- nLiven PR Human Platelet Lysate A GMP-ready pathogen-reduced human platelet lysate with E-Beam irradiation pathogen reduction meeting EU Pharmacopoeia standards and a Biodefined composition that reduces lot-to-lot variability compared to traditional PL preparations.
- T-Liven PR Human Platelet Lysate A GMP-ready human platelet lysate for closed-system bioprocessing with release against a T cell growth release assay for optimal immune cell quality. Available in bag format.
- Signata CT-5 A compact, benchtop aliquoting system that enables automated, aseptic filling into vials (including CellSeal Cryogenic Vials) without the need for a biosafety cabinet. Features an intuitive touchscreen interface and pre-configured fill protocols.
- CellSeal Connect Closed-system transfer vials with weldable fill and retrieval and vent tubes, designed for closed-system introduction of intermediate reagents for activation, transduction, and expansion.
- CellSeal CryoCase A rigid cryopreservation container designed for CGT storage, engineered as the first rigid container for closed-system fill and retrieval of larger volumes of fluid (<75 mL), with a documented reduction in particulates compared to traditional cryobags.
- CryoStor Freeze Media Proprietary freeze media intended for cryopreservation of biologics at -196°C to -70°C, proven more effective in reducing post-preservation apoptosis and necrosis than commercial and home-brew isotonic and extracellular formulations.
- HypoThermosol FRS Freeze Media A novel, engineered, optimized hypothermic storage and shipping media. Serum-free and protein-free, designed to provide maximum storage and shipping stability for cells and tissues at 2-8°C.
- BloodStor Freeze Media A pure media product containing various levels of DMSO concentration from 27% to 100% DMSO, in Saline or Dextran, sterilized, tested for endotoxins, and manufactured under cGMPs with USP-grade components.
- Cell Thawing Media Cell and tissue thawing products developed to address a Dextran shortage in the leukapheresis industry; blood products require an added buffer for long-term storage.
- Bio-T Intra-campus transport solution for biopreservation.
Quantifiable outcome
- CryoStor and HypoThermosol FRS embedded in 700+ customer clinical applications
- +3 more outcomes
Companies that use Sexton Biotechnologies
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Sexton Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Sexton Biotechnologies partnerships and signals
Strategic signalScale indicators3 records
Recent moves1 record
Expansion highlights1 record
Sexton Biotechnologies competitors and assessment
Company assessmentDirect peers
- BioLife Solutions: Publicly listed parent/strategic investor (NASDAQ: BLFS) and source of virtually all Sexton product, customer and certification data; offers an overlapping portfolio of CryoStor, HypoThermosol FRS, BloodStor, CellSeal vials, Signata CT-5 and hPL products into the same CGT and biobanking customers.
- STEMCELL Technologies: Specialist supplier of cell-isolation, cell-culture media and cryopreservation reagents for regenerative medicine and immuno-oncology research, addressing the same hPL/cryopreservation use cases as Sexton's Stemulate and CryoStor lines.
Broad incumbents
- Cytiva: Global life-science tools and bioprocessing supplier (formerly GE Healthcare Life Sciences) offering cell-culture media, cryopreservation reagents and CGT workflow solutions to overlapping biopharma, CDMO and academic customers.
- Thermo Fisher Scientific: Diversified life-science incumbent with a dedicated CGT and cell-therapy services portfolio including cryopreservation media, cell-culture supplements and ancillary materials sold into the same biopharma and CDMO buyer base.
- Lonza Group: Global CDMO and cell-therapy media supplier offering cell-culture media, cryopreservation solutions and process-development services to CGT developers and CDMOs - overlapping with Sexton's biopreservation and hPL media offering.
- Corning Life Sciences: Major cell-culture media, cryogenic vials and bioprocessing consumables manufacturer serving biopharma and research customers with products that directly overlap Sexton's media and closed-system vial portfolio.
- FUJIFILM Irvine Scientific: Industrial cell-culture media manufacturer supplying GMP-grade media and supplements for cell therapy and regenerative medicine manufacturers, competing head-on with Sexton's hPL and biopreservation media.
- Miltenyi Biotec: Cell-processing instruments, reagents and GMP-grade media supplier for cell and gene therapy developers, overlapping with Sexton's cell-processing, media and closed-system handling portfolio.
- Sartorius: Bioprocessing equipment and consumables supplier whose cell-and-gene-therapy portfolio of single-use systems, media and process services competes for the same CDMO and therapy-developer budgets.
Emerging players
- Vineti: CGT-specific software and workflow provider for chain-of-custody, manufacturing orchestration and patient logistics; not a direct media peer but embedded in the same CGT commercial workflow and buyer set.
Market position
Strengths5 records
Weaknesses5 records
Key risks6 records
Key highlights7 records
Customer concentration
Sexton Biotechnologies social profiles
Digital presenceSexton Biotechnologies compliance and trust
Trust signalCompliance4 records
Sexton Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sexton Biotechnologies leadership team
Management profileNumber of profiles
Profiles2 records
Sexton Biotechnologies funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sexton Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sexton Biotechnologies
What does Sexton Biotechnologies do?
Sexton Biotechnologies is a private biotechnology company based in Indianapolis, founded in 2019. Per the available company and product data, it is associated with a portfolio of biopreservation media, human platelet lysate cell performance products, and automated cell processing and cryogenic storage equipment used in cell and gene therapy manufacturing workflows. Its offerings span freeze and storage media, pathogen-reduced platelet lysates, and closed-system fill/finish and cryogenic handling instruments.
Is Sexton Biotechnologies a public or private company?
Sexton Biotechnologies is a public company. It is classified as venture growth investor backed and is currently operating.
When was Sexton Biotechnologies founded?
Sexton Biotechnologies was founded in 2019. It employs 11 to 50 people.
Where is Sexton Biotechnologies based?
Sexton Biotechnologies is headquartered in Indianapolis, United States, in the North America region.
How does Sexton Biotechnologies make money?
Four revenue lines are on record. Biopreservation Media Products are the primary driver. The others are cell Performance Solutions, processing and Handling Equipment and regulatory Support Services.
Who are Sexton Biotechnologies's main competitors?
Direct peers on record are BioLife Solutions and STEMCELL Technologies. Broad incumbents are Cytiva, Thermo Fisher Scientific, Lonza Group, Corning Life Sciences, FUJIFILM Irvine Scientific, Miltenyi Biotec and Sartorius. Vineti is listed as an emerging player.
Does Sexton Biotechnologies have an API?
No public API is recorded for Sexton Biotechnologies.
What industry is Sexton Biotechnologies in?
Sexton Biotechnologies's product category is Biopreservation and Cell Processing Products. Its primary akta.pro industry code is HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats), with a secondary code of HLAGAGAK, Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low). Its NAICS code is 325414 and its SIC code is 2836.